Latest CervoMed News & Updates

See the latest news and media coverage for CervoMed. We track all announcements, press releases, and industry mentions in real time, all in one place.

CervoMed

Clinical-stage biotechnology company developing treatments for age-related brain disorders

cervomed.com

Headquarters: Boston, United States
Founded year: 2023
Company type: Public company
Number of employees: 20–50
Industry: Biotechnology & Medical Research

Last updated October 12

Latest news about CervoMed

In short: CervoMed reported nfvPPA biomarker data and advanced neflamapimod toward Phase 3 for DLB.

Company announcements

October 12 CervoMed

CervoMed reports initial biomarker data from Phase 2a neflamapimod trial

Results show reduced neurofilament light levels over 12 weeks in nfvPPA patients at the ISFTD meeting. Further data is expected later this year.

September 28 CervoMed

CervoMed announces new tablet formulation and FDA approval

The company introduces a 50 mg oral tablet for neflamapimod, securing FDA removal of exposure limits to enable a twice-daily dosing regimen.

September 10 CervoMed

CervoMed announces initial clinical trial data for neflamapimod in nfvPPA

The twelve-week biomarker findings will be presented at the ISFTD Annual Meeting in October to support ongoing neurodegenerative disease development.

August 10 CervoMed

CervoMed reports Q2 2026 financial results and corporate updates

The company is prioritizing a strategic partnership to advance neflamapimod into Phase 3 for DLB, and presented new analyses at AAIC 2026.

Media coverage

October 11 The Globe and Mail

CervoMed reports encouraging biomarker data in Phase 2a trial

On October 12, 2026, CervoMed reported initial 12-week biomarker data from the open-label portion of its Phase 2a trial of neflamapimod in nonfluent variant primary...

August 9 The Manila Times

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) ...

March 24 Yahoo Finance

CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

CervoMed Inc. (NASDAQ:CRVO) earns a place on our top 10 stocks under $5 that could triple. On March...

November 4, 2025 Yahoo Finance

CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies

FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New...

Never miss news about CervoMed

Track CervoMed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

CervoMed competitors & trending companies

Browse news for competitors to CervoMed and other trending companies.